AETHLON MEDICAL INC (AEMD)
Aethlon Medical Inc, trading under ticker AEMD, is a public company engaged in the development of proprietary medical device and therapeutic technologies. Headquartered in San Diego, California, Aethlon focuses on extracorporeal blood purification and immune-modulation platforms designed to address infectious diseases and other therapeutic needs.
What the company does
Aethlon Medical develops medical devices that operate on extracorporeal principles—meaning they work outside the body to treat blood or other biological fluids. The company’s primary platform involves proprietary technologies designed to selectively bind and remove pathogens, toxins, and other harmful particles from patient blood or plasma. These devices are intended for use in hospitals, clinical centers, and other therapeutic settings where infectious disease or immune challenges require intervention.
How it makes money
The company operates as a development-stage medical technology company. Revenue generation depends on commercializing its device platforms through regulatory approval, clinical adoption, and licensing partnerships. Income sources include potential royalties from licensing agreements, milestone payments from collaborative partners, and eventual product sales once devices achieve market clearance. The company also manages research grants and funding to support ongoing development.
Research and development focus
Medical device development requires sustained investment in research, clinical trials, regulatory submissions, and manufacturing process refinement. Aethlon’s R&D pipeline includes devices targeting multiple disease areas, with advancement dependent on clinical evidence, regulatory pathways, and partnership opportunities. Like all biomedical device firms, the company faces regulatory risk tied to FDA approval and international market access, as well as execution risk in clinical trials and commercialization.
Market position and competition
The blood purification and immune-modulation device market includes both established medical device firms with large product portfolios and specialized smaller companies. Aethlon operates as a focused technology developer competing on innovation and specialized capability in its core technology domains. Success depends on demonstrating clinical utility, achieving regulatory approval, and establishing partnerships or direct commercial pathways to healthcare providers.
How to research it
Aethlon files annual 10-K reports and quarterly 10-Q filings with the U.S. Securities and Exchange Commission, disclosing research progress, clinical trial status, regulatory developments, and financial position. The company also issues press releases regarding clinical milestones and partnership announcements. Investors can review FDA filings, clinical trial registries, and industry research on immune-modulation and blood purification technology trends.